Briviact (in Italy: Nubriveo)

RSS

brivaracetam

Authorised
This medicine is authorised for use in the European Union.

Overview

Briviact is an epilepsy medicine used as an add-on to other epilepsy medicines to treat partial-onset seizures (epileptic fits starting in one specific part of the brain). It can be used in patients from the age of 2 years with partial-onset seizures with or without secondary generalisation (where the abnormal electrical activity spreads through the brain). Briviact contains the active substance brivaracetam.

This EPAR was last updated on 10/11/2022

Authorisation details

Product details
Name
Briviact (in Italy: Nubriveo)
Agency product number
EMEA/H/C/003898
Active substance
Brivaracetam
International non-proprietary name (INN) or common name
brivaracetam
Therapeutic area (MeSH)
Epilepsy
Anatomical therapeutic chemical (ATC) code
N03AX23
Publication details
Marketing-authorisation holder
UCB Pharma SA
Revision
18
Date of issue of marketing authorisation valid throughout the European Union
13/01/2016
Contact address
Allée de la Recherche 60
1070 Bruxelles
Belgium

Product information

24/02/2022 Briviact (in Italy: Nubriveo) - EMEA/H/C/003898 - II/0032/G

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antiepileptics

Therapeutic indication

Briviact is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy.

Assessment history

Changes since initial authorisation of medicine

Related content

How useful was this page?

Add your rating
Average
6 ratings
1 rating
1 rating